The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model
Open accessAbstract
The potential of inhibitory metabolites of perpetrator drugs to contribute to drug-drug interactions (DDIs) is uncommon and underestimated. However, the occurrence of unexpected DDI suggests the potential contribution of metabolites to the observed DDI. The aim of this study was to develop a physiologically-based pharmacokinetic (PBPK) model for bupropion and its three primary metabolites—hydroxybupropion, threohydrobupropion and erythrohydrobupropion—based on a mixed “bottom-up” and “top-down” approach and to contribute to the understanding of the involvement and impact of inhibitory metabolites for DDIs observed in the clinic. PK profiles from clinical researches of different dosages were used to verify the bupropion model. Reasonable PK profiles of bupropion and its metabolites were captured in the PBPK model. Confidence in the DDI prediction involving bupropion and co-administered CYP2D6 substrates could be maximized. The predicted maximum concentration (Cmax) area under the concentration-time curve (AUC) values and Cmax and AUC ratios were consistent with clinically observed data. The addition of the inhibitory metabolites into the PBPK model resulted in a more accurate prediction of DDIs (AUC and Cmax ratio) than that which only considered parent drug (bupropion) P450 inhibition. The simulation suggests that bupropion and its metabolites contribute to the DDI between bupropion and CYP2D6 substrates. The inhibitory potency from strong to weak is hydroxybupropion, threohydrobupropion, erythrohydrobupropion, and bupropion, respectively. The present bupropion PBPK model can be useful for predicting inhibition from bupropion in other clinical studies. This study highlights the need for caution and dosage adjustment when combining bupropion with medications metabolized by CYP2D6. It also demonstrates the feasibility of applying the PBPK approach to predict the DDI potential of drugs undergoing complex metabolism, especially in the DDI involving inhibitory metabolites.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rodgers, T., & Rowland, M. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20502 · Cited by 946
Predicting in vivo drug interactions from in vitro drug discovery data
Wienkers, L. C., & Heath, T. G. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1851 · Cited by 904
Poulin, P., & Theil, F. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10005 · Cited by 568
The Simcyp ® Population-based ADME Simulator
Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G., & Rostami-Hodjegan, A. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802691074 · Cited by 533
Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations
Jefferson, J. W., Pradko, J. F., & Muir, K. T. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.11.011 · Cited by 408
Hesse, L. M., Venkatakrishnan, K., Court, M. H., von Moltke, L. L., Duan, S. X., Shader, R. I., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12046-9 · Cited by 397
Faucette, S. R., Hawke, R. L., Lecluyse, E. L., Shord, S. S., Yan, B., Laethem, R. M., & Lindley, C. M. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12054-8 · Cited by 353
A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics
Jones, H. M., Parrott, N., Jorga, K., & Lav??, T. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645050-00006 · Cited by 352
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6
Kirchheiner, J., Klein, C., Meineke, I., Sasse, J., Zanger, U. M., M??rdter, T. E., Roots, I., & Brockm??ller, J. (2003) · Pharmacogenetics · doi:10.1097/00008571-200310000-00005 · Cited by 249
Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective
Prueksaritanont, T., Chu, X., Gibson, C., Cui, D., Yee, K. L., Ballard, J., Cabalu, T., & Hochman, J. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9470-x · Cited by 248
Rostami-Hodjegan, A., & Tucker, G. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.10.002 · Cited by 239
Damaj, M. I., Carroll, F. I., Eaton, J. B., Navarro, H. A., Blough, B. E., Mirza, S., Lukas, R. J., & Martin, B. R. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.001313 · Cited by 212
Zhao, P., Rowland, M., & Huang, S.-M. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.68 · Cited by 212
Fahmi, O. A., Maurer, T. S., Kish, M., Cardenas, E., Boldt, S., & Nettleton, D. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018663 · Cited by 204
Regulatory Experience With Physiologically Based Pharmacokinetic Modeling for Pediatric Drug Trials
Leong, R., Vieira, M. L. T., Zhao, P., Mulugeta, Y., Lee, C. S., Huang, S.-M., & Burckart, G. J. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.19 · Cited by 187
Rowland Yeo, K., Jamei, M., Yang, J., Tucker, G. T., & Rostami-Hodjegan, A. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.12.002 · Cited by 186
Fogelman, S. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00113-4 · Cited by 175
Huang, S. M., & Lesko, L. J. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004265367 · Cited by 151
The Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review
Huang, S.-M., & Rowland, M. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.320 · Cited by 150
Multiplicity of Mammalian Reductases for Xenobiotic Carbonyl Compounds
Matsunaga, T., Shintani, S., & Hara, A. (2006) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.21.1 · Cited by 150
Inhibition of CYP2D6 Activity by Bupropion
Kotlyar, M., Brauer, L. H., Tracy, T. S., Hatsukami, D. K., Harris, J., Bronars, C. A., & Adson, D. E. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000162805.46453.e3 · Cited by 144
Pharmacokinetics of Bupropion and its Metabolites in Cigarette Smokers versus Nonsmokers
Hsyu, P., Singh, A. K., Giargiari, T. D., Dunn, J. A., Ascher, J. A., & Johnston, J. A. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb04361.x · Cited by 137
Combining Bupropion SR With Venlafaxine, Paroxetine, or Fluoxetine
Kennedy, S. H., McCann, S., Masellis, M., McIntyre, R. S., Raskin, J., McKay, G., & Baker, G. B. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0302 · Cited by 135
Bupropion in Depression: II. The Role of Metabolites in Clinical Outcome
Golden, R. N., Vane, C. L. D., Laizure, S. C., Rudorfer, M. V., Sherer, M. A., & Potter, W. Z. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800260055007 · Cited by 125
Metabolism and kinetics of bupropion.
Dh, S. (1983) · PubMed · Cited by 121
Kato, M., Shitara, Y., Sato, H., Yoshisue, K., Hirano, M., Ikeda, T., & Sugiyama, Y. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9607-2 · Cited by 115
Parrott, N., Paquereau, N., Coassolo, P., & Lavé, T. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20419 · Cited by 107
Carbamazepine but not Valproate Induces Bupropion Metabolism
Ketter, T. A., Jenkins, J. B., Schroeder, D. H., Pazzaglia, P. J., Marangell, L. B., George, M. S., Callahan, A. M., Hinton, M. L., Chao, J. Y., & Post, R. M. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199510000-00004 · Cited by 107
Ereshefsky, L., & Dugan, D. J. (2000) · Depression and Anxiety · doi:10.1002/1520-6394(2000)12:1+<30::aid-da4>3.0.co;2-g · Cited by 106
Varma, M. V. S., Lai, Y., Kimoto, E., Goosen, T. C., El‐Kattan, A. F., & Kumar, V. S. (2013) · Pharmaceutical Research · doi:10.1007/s11095-012-0956-5 · Cited by 105
Buck, S. S. D., Sinha, V. K., Fenu, L. A., Gilissen, R., Mackie, C. E., & Nijsen, M. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.014027 · Cited by 104
Findlay, J. W. A., Fleet, J. V. W., Smith, P., Butz, R. F., Hinton, M. L., Blum, M. R., & Schroeder, D. H. (1981) · European Journal of Clinical Pharmacology · doi:10.1007/bf00637513 · Cited by 103
Loboz, K. K., Gross, A. S., WILLIAMS, K., Liauw, W., Day, R. O., Blievernicht, J., Zanger, U. M., & McLachlan, A. J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.010 · Cited by 98
Zhang, X., Quinney, S. K., Gorski, J. C., Jones, D. R., & Hall, S. D. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.026658 · Cited by 97
Self-citationBehavioral and biochemical investigations of bupropion metabolites
Bondarev, M. L., Bondareva, T. S., Young, R., & Glennon, R. A. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)02010-7 · Cited by 93
Application of PBPK modelling in drug discovery and development at Pfizer
Jones, H. M., Dickins, M., Youdim, K., Gosset, J. R., Attkins, N. J., Hay, T. L., Gurrell, I. K., Logan, Y. R., Bungay, P. J., Jones, B. C., et al. (2012) · Xenobiotica · doi:10.3109/00498254.2011.627477 · Cited by 92
Drug-drug interactions of new active substances: mibefradil example
Jc, K., Vožeh, S., Kondo-Oestreicher, M., et al. (1999) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050673 · Cited by 91
CYP2B6 and Bupropion’s Smoking-Cessation Pharmacology: The Role of Hydroxybupropion
Zhu, A. Z. X., Cox, L. S., Nollen, N. L., Faseru, B., Okuyemi, K. S., Ahluwalia, J. S., Benowitz, N. L., & Tyndale, R. F. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.186 · Cited by 88
Palovaara, S. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00202-9 · Cited by 87
An in Vitro Mechanistic Study to Elucidate the Desipramine/Bupropion Clinical Drug-Drug Interaction
Reese, M. J., Wurm, R. M., Muir, K. T., Generaux, G. T., John‐Williams, L. S., & McConn, D. J. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.020198 · Cited by 84
HPLC assay for bupropion and its major metabolites in human plasma
Loboz, K. K., Gross, A. S., Ray, J. E., & McLachlan, A. J. (2005) · Journal of Chromatography B · doi:10.1016/j.jchromb.2005.06.009 · Cited by 75
Single‐Dose Pharmacokinetics of Bupropion in Adolescents: Effects of Smoking Status and Gender
Stewart, J. J., Berkel, H. J., Parish, R. C., Simar, M. R., Syed, A., Bocchini, J. A., Wilson, J. T., & Manno, J. E. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010564 · Cited by 74
Fenneteau, F., Poulin, P., & Nekka, F. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21802 · Cited by 73
Yeung, C. K., Fujioka, Y., Hachad, H., Lévy, R. H., & Isoherranen, N. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.252 · Cited by 72
Yamazaki, S., Skaptason, J., Romero, D., Vekich, S., Jones, H. M., Tan, W., Wilner, K. D., & Koudriakova, T. B. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035857 · Cited by 68
Vossen, M., Sevestre, M., Niederalt, C., Jang, I., Willmann, S., & Edginton, A. N. (2007) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-4-13 · Cited by 67
Isoherranen, N., Hachad, H., Yeung, C. K., & Levy, R. H. (2009) · Chemical Research in Toxicology · doi:10.1021/tx800491e · Cited by 64
Perdaems, N., Blasco, H., Vinson, C., Chenel, M., Whalley, S., Cazade, F., & Bouzom, F. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318130-000000000-00000 · Cited by 63
Physiologically Based Pharmacokinetic Modeling: From Regulatory Science to Regulatory Policy
Sinha, V. P., Zhao, P., Huang, S. M., & Zineh, I. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.46 · Cited by 58
Effects of Hydroxymetabolites of Bupropion on Nicotine Dependence Behavior in Mice
Damaj, M. I., Grabus, S. D., Navarro, H. A., Vann, R. E., Warner, J. A., King, L. S., Wiley, J. L., Blough, B. E., Lukas, R. J., & Carroll, F. I. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166850 · Cited by 54
Posner, J., Bye, A., Dean, K., Peck, A. W., & Whiteman, P. D. (1985) · European Journal of Clinical Pharmacology · doi:10.1007/bf00547376 · Cited by 53
Metabolism of Bupropion by Carbonyl Reductases in Liver and Intestine
Connarn, J. N., Zhang, X., Babiskin, A. H., & Sun, D. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.063107 · Cited by 52
Self-citationSiccardi, M., Marzolini, C., Seden, K., Almond, L. M., Kirov, A., Khoo, S., Owen, A., & Back, D. J. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0056-7 · Cited by 51
Chen, Y., Mao, J., & Hop, C. E. C. A. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.059311 · Cited by 51
Pharmacokinetics of Bupropion and Its Metabolites in Haemodialysis Patients Who Smoke
Worrall, S. P. R., Almond, M. K., & Dhillon, S. (2004) · Nephron Clinical Practice · doi:10.1159/000078635 · Cited by 48
Sager, J. E., Tripathy, S., Price, L., Nath, A., Chang, J. S., Stephenson‐Famy, A., & Isoherranen, N. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.007 · Cited by 47
Steady-State Pharmacokinetics of Bupropion SR in Juvenile Patients
Daviss, W. B., Perel, J. M., Rudolph, G. R., Axelson, D., Gilchrist, R., Nuss, S., Birmaher, B. B., & Brent, D. A. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000153225.26850.26 · Cited by 44
Kudo, T., Hisaka, A., Sugiyama, Y., & Ito, K. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.049460 · Cited by 39
Hesse, L. M., Greenblatt, D. J., Moltke, L. L., et al. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006286981 · Cited by 35
Jiang, F., Kim, H.-D., Na, H. S., Lee, S., Seo, D.-W., Choi, J.-Y., Ha, J.-H., Shin, H.-J., Kim, Y.-H., & Chung, M. W. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3825-6 · Cited by 34
Masters, A. R., Gufford, B. T., Lu, J. B. L., Metzger, I. F., Jones, D. R., & Desta, Z. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.232876 · Cited by 33
PBPK as a tool in regulatory review
Huang, S. M. (2012) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1777 · Cited by 30
Dash, R. P., Rais, R., & Srinivas, N. R. (2017) · Xenobiotica · doi:10.1080/00498254.2017.1376765 · Cited by 15
Cited by
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Biomedical applications of hydrogels in drug delivery system: An update
Kesharwani, P., Bisht, A., Alexander, A., Dave, V., & Sharma, S. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102914 · Cited by 288
Biocompatible ionic liquids and their applications in pharmaceutics
Md Moshikur, R., Chowdhury, M. R., Moniruzzaman, M., & Goto, M. (2020) · Green Chemistry · doi:10.1039/d0gc02387f · Cited by 268
mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo
Rybakova, Y., Kowalski, P. S., Huang, Y., Gonzalez, J. T., Heartlein, M. W., DeRosa, F., Delcassian, D., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.012 · Cited by 218
Akbar, D., Rhee, T. G., Ceban, F., Ho, R., Teopiz, K. M., Cao, B., Subramaniapillai, M., Kwan, A. T. H., Rosenblat, J. D., & McIntyre, R. S. (2023) · CNS Drugs · doi:10.1007/s40263-023-01032-5 · Cited by 38
Metadata
- Authors
- Xue, C., Zhang, X., & Cai, W.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2017-12-21
- Volume
- 10
- Issue
- 1
- Pages
- 1
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W2778886043
- Cited by
- 291
- References
- 63
- FWCI
- 38.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.